Q2 FY2026 EarningsQ2 FY26 results were mixed relative to consensus: revenue of $150K slightly beat the $149K expectation, while GAAP EPS of -$0.15 missed the -$0.1387 mean estimate due to R&D acceleration. Operating loss of $48.4M was deeper than the expected $47.0M EBIT loss, driven by $36.1M in R&D spend as Phase 3 PROACT 1 clinical trials progressed. The company issued a 'going concern' warning, noting that its $181.6M in liquidity is insufficient to fund operations beyond mid-2027 without additional capital.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: ProKidney(PROK) the Revenue is 150 K (-32.13%), Beat estimate;the EBIT is -48.37 M (-21.82%), Miss estimate;the EPS is -0.15 (-15.38%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B32.13%
0.00B32.58%
+0.00B0.45%
EBITMiss expectations
-0.05B21.82%
-0.05B18.28%
-0.00B3.54%
EPSMiss expectations
-0.1515.38%
-0.13876.68%
-0.01138.70%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf